Home Alzheimer’s Disease Pashtoon Murtaza Kasi, MD, MSc, on the Use of an AI-Driven Clinical...

Pashtoon Murtaza Kasi, MD, MSc, on the Use of an AI-Driven Clinical Trial Support Tool

A study presented at the 2021 American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium found that a novel patient-focused, artificial intelligence (AI)–driven clinical trial support tool can aid in providing patients access to clinical trials.

The novel search tool, which can be found at www.ancora.ai, uses AI to restructure trial information. By democratizing trial information, investigators suggested that trial accrual as well as patient satisfaction will increase as disparities decrease simultaneously.

In an interview with CancerNetwork®, Pashtoon Murtaza Kasi, MD, MSc, of the University of Iowa, explained what such a platform could afford both oncologic providers and patients.


You know, I think the same problem that patients and caregivers face, [providers]…seem to face the same issue every day. The nice thing about some of these trials is…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Robert J. Motzer, MD, on Outcomes of the Phase 3 CheckMate 9ER Trial in Advanced RCC

According to results of a subgroup analysis from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO)...

Patients Aged 70 or Older With Esophageal or EGJ Cancers Should Be Evaluated for Optimal Curative Therapy

Older patients with locoregional esophageal or esophagogastric junction (EGJ) cancer need to be evaluated for optimal curative therapy, including neoadjuvant chemoradiotherapy and surgical resection,...

Third COVID-19 Vaccine Earns Emergency Use Authorization Following Favorable Advisory Committee Meeting

The first single-dose COVID-19 vaccine was granted Emergency Use Authorization (EUA) by the FDA, according to its developer Janssen Pharmaceutical Companies of Johnson &...

Abiraterone Acetate, Apalutamide Likeliest to Improve Survival for Patients with Castration-Sensitive Prostate Cancer

In a comparison of systemic treatments as add-ons to androgen-deprivation therapy (ADT) for patients with metastatic castration-sensitive prostate cancer (mCSPC), abiraterone acetate (Zytiga) and...

Recent Comments